SPHINGOSINE-1-PHOSPHATE AS A NEW DIAGNOSTIC, PROGNOSTIC BIOMARKER FOR PROSTATE CANCER AND EFFECTIVENESS OF INTENSITY-MODULATED RADIATION THERAPY-Reference-Cited by-同舟云学术

SPHINGOSINE-1-PHOSPHATE AS A NEW DIAGNOSTIC, PROGNOSTIC BIOMARKER FOR PROSTATE CANCER AND EFFECTIVENESS OF INTENSITY-MODULATED RADIATION THERAPY

Published:2023 Issue:84 Volume:19 Page:93
ISSN:2079-8334
Container-title:World of Medicine and Biology
language:en
Short-container-title:WOMAB

Author:

Komarevtsev V. N.¹,Balabanova K. V.¹,Frolova I. V.¹,Komarevtseva I. O.¹,Shipilov K. V.¹,Seryogina N. M.¹,Moraru-Burlescu R. Р.¹

Affiliation:

1. Lugansk State Medical University

Publisher

Scientific Society Anatomists, Histologists, and Embryologists, Ukraine

Subject

General Medicine

Reference15 articles.

1. Komarevtseva ІO, Chebotarova AA. Vplyv zastosuvannya apoptoz-іndukovanykh mezenkhіmalnykh stovburovykh klіtyn na rіven fragmentatsіyi DNK і aktyvnіst systemy sfіngozynu v umovakh eksperymentalnoho modelyuvannya patolohіchnoho protsesu. Medychna ta klіnіchna khіmіya. 2016. 18(1): 19–23.

2. Agrawal R, Dey A, Datta S. Pattern of Radiotherapy Treatment in Low-Risk, Intermediate-Risk, and High-Risk Prostate Cancer Patients: Analysis of National Cancer Database. Cancers (Basel). 2022; 14(22). doi:10.3390/cancers14225503

3. Cheng JC, Bai A, Beckham TH. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013;123(10):4344–4358. doi:10.1172/JCI64791

4. Cozzi S, Ruggieri MP, Alì E. Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients. In Vivo. 2023;37(2):777–785. doi:10.21873/invivo.13141

5. Hara D, Tao W, Schmidt RM. Boosted Radiation Bystander Effect of PSMA-Targeted Gold Nanoparticles in Prostate Cancer Radiosensitization. Nanomaterials. 2022;12(24). doi:10.3390/nano12244440